Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Platelet glycoprotein Ilb/IIIa

Deshmukh VR, Fiorella DJ, Albuquerque FC, Frey J, Flaster M, Wallace RC, Spetzler RF, McDougall CG. Intra-arterial thrombolysis for acute ischemic stroke preliminary experience with platelet glycoprotein Ilb/IIIa inhibitors as adjunctive therapy. Neurosurgery 2005 56 46-54 [discussion 54 5]. [Pg.95]

Lefkovits J., Plow E. F., Topol E. Platelet glycoprotein Ilb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995 332, 1553-9. [Pg.163]

Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM et al. Economic assessment of platelet glycoprotein Ilb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996 94 629-35. [Pg.54]

Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N et al. Outcomes at 1 year and economic imphcations of platelet glycoprotein Ilb/IIIa blockade in patients undergoing coronary stenting results from a multicentre randomised trial. EPISTENT investigators. Evaluation of platelet Ilb/IIIa inhibitor for stenting. Lancet 1999 354 2019-24. [Pg.55]

C. Aspirin inhibits platelet cyclooxygenase. Abciximab, a monoclonal antibody, binds to and inhibits the platelet glycoprotein Ilb/IIIa receptor. Dipyridamole inhibits platelet cyclic AMP phosphodiesterase and raises cyclic AMP levels. Eptifibatide binds to the glycoprotein Ilb/IIIa complex. [Pg.266]

Mousa SA. Antiplatelet therapies Recent advances in the development of platelet glycoprotein Ilb/IIIa antagonists. Curr Interv Cardiol Rep 1999 1 243-252. [Pg.267]

Topol EJ, Moliterno DJ, Hermann HC, Powers ER, et al. 2001. Comparison of two platelet glycoproteins Ilb/IIIa inhibitors, Tirofiban and abciximab, for the prevention of ischemic events with precutaneous coronary revascularization. NEJM. 344 1888-1894. [Pg.126]

Atwater BD, Roe MT, Mahaffey KW. Platelet glycoprotein Ilb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes a review and guide to patient selection. Drugs. 2005 65 313-324. [Pg.317]

Anne G, Gruberg L. Platelet glycoprotein Ilb/IIIa inhibitors during percutaneous coronary interventions a pharmacological and clinical review. Expert Opin Pharmacother. 2004 5 335-348. [Pg.363]

Coller, B. S. (1985). A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein Ilb/IIIa complex./. Clin. Invest. 76, 101-108. [Pg.406]

Bates, E. R., McGillem, M. J., Mickelson, J. K, Pitt, B., and Mancini, G. B. (1991). A monoclonal antibody against the platelet glycoprotein Ilb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 84, 2463-2469. [Pg.406]

Ellis, S. G., Tcheng, J. E., Navetta, F. I., Muller, D. W. M., Weisman, H. F., Smith, C., Anderson, K. M., Califf, R. M., and Topol, E. J. (1993). Safety and anti-platelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein Ilb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Dis. 4, 167-175. [Pg.406]

EPILOG Investigators (1997). Platelet glycoprotein Ilb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Enol. J. Med. 336, 1689-1696. [Pg.406]

Brener, S., Barr, L. A., Burchenal, J. et al. (1998). Randomised placebo-controlled trial of platelet glycoprotein Ilb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98, 734—741. [Pg.406]

Simon, D. I., Xu, H., Ortlepp, S. et al. (1997). 7E3 monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler. Thromb. Vase. Biol. 17, 528-535. [Pg.407]

Khurana S, Mattson JC, Westley S et al. (1997) Monitoring platelet glycoprotein Ilb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 130 401—411... [Pg.258]

Platelet glycoprotein Ilb-IIIa receptor binding is given as fmol 125I-fibrinogen/108 platelets or 125I-fibrinogen molecules bound per platelet. [Pg.264]

Coller BS, Folts JD, Scudder LE, Smith SR (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein Ilb/IIIa receptor in an experimental animal model. Blood 68 783-786... [Pg.317]

Ohman EM, Kleiman NS, Gacioch G et al. (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein Ilb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 95 846-854 [Comment in Circulation (1997) 95 793-795]... [Pg.317]

Scarborough, R. M., and Gretler, D. D. (2000). Platelet glycoprotein Ilb-IIIa antagonists as prototypical integrin blockers Novel parenteral and potential oral antithrombotic agents. /. Med. Chem. 43, 3453-3473. [Pg.61]

Parise LV, Helgerson SL, Steiner B, Nannizzi L, Phillips DR. Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein Ilb-IIIa. J. Biol. Chem. 1987 262 12597-12602. [Pg.784]

Du XP, Plow EF,FrelingerAL 3d, etal. Platelet glycoprotein Ilb-IIIa (alpha nb beta 3 integrin) confers fibrinogen-and activation-dependent aggregation on heterologous cells. Blood 1991 78 369-376. [Pg.183]

Eccleston D, Topol EJ. Inhibitors of platelet glycoprotein Ilb/IIIa as augmenters of thrombolysis. Coronary Artery Dis 1995 6 947-955. [Pg.187]

Wang R, Peterson J, Aster RH, Newman PJ Disruption of a long-range disulfide bond between Cys and CySfjj in glycc otein Ilia does not affect the function of platelet glycoprotein Ilb-IIIa Blood 1718-1719,1997. [Pg.417]

The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa... [Pg.546]

Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3, which binds to the platelet glycoprotein Ilb/IIIa receptor and inhibits platelet aggregation (1). [Pg.3]

See other pages where Platelet glycoprotein Ilb/IIIa is mentioned: [Pg.600]    [Pg.56]    [Pg.373]    [Pg.119]    [Pg.264]    [Pg.192]    [Pg.228]    [Pg.411]    [Pg.474]    [Pg.474]    [Pg.406]    [Pg.34]    [Pg.396]    [Pg.215]    [Pg.258]    [Pg.261]    [Pg.317]    [Pg.319]    [Pg.546]    [Pg.583]    [Pg.2810]    [Pg.5]   


SEARCH



Glycoprotein Ilb/IIIa

Platelet glycoprotein

© 2024 chempedia.info